www.nature.com/scientificreports
OPEN
received: 14 December 2016 accepted: 02 March 2017 Published: 04 April 2017
Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device Mohammad A. Qasaimeh1,2,3,*, Yichao C. Wu3,*, Suman Bose3,†, Anoop Menachery1, Srikanth Talluri4,5, Gabriel Gonzalez4, Mariateresa Fulciniti5, Jeffrey M. Karp6, Rao H. Prabhala4,5,7,8 & Rohit Karnik3 The necessity for bone marrow aspiration and the lack of highly sensitive assays to detect residual disease present challenges for effective management of multiple myeloma (MM), a plasma cell cancer. We show that a microfluidic cell capture based on CD138 antigen, which is highly expressed on plasma cells, permits quantitation of rare circulating plasma cells (CPCs) in blood and subsequent fluorescencebased assays. The microfluidic device is based on a herringbone channel design, and exhibits an estimated cell capture efficiency of ~40–70%, permitting detection of
OPEN
received: 14 December 2016 accepted: 02 March 2017 Published: 04 April 2017
Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device Mohammad A. Qasaimeh1,2,3,*, Yichao C. Wu3,*, Suman Bose3,†, Anoop Menachery1, Srikanth Talluri4,5, Gabriel Gonzalez4, Mariateresa Fulciniti5, Jeffrey M. Karp6, Rao H. Prabhala4,5,7,8 & Rohit Karnik3 The necessity for bone marrow aspiration and the lack of highly sensitive assays to detect residual disease present challenges for effective management of multiple myeloma (MM), a plasma cell cancer. We show that a microfluidic cell capture based on CD138 antigen, which is highly expressed on plasma cells, permits quantitation of rare circulating plasma cells (CPCs) in blood and subsequent fluorescencebased assays. The microfluidic device is based on a herringbone channel design, and exhibits an estimated cell capture efficiency of ~40–70%, permitting detection of
